Cell and Gene Therapy Strategic Roundup | Jul 29 – Aug 31, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
Genprex and Roche Diagnostics begin TROP2 assay validation to support…
Cell and Gene Therapy Strategic Roundup | June 24–July 29, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Sickle Cell Gene Therapies Ranked by AI Models | LucidScope AI Visibility Audit
Key Findings from the LucidScope AI Visibility Audit of Casgevy, Lyfgenia,…
Public Health Today—June 12, 2026
This weekly public health update highlights major developments across…
Lucid Diligence Brief: Genethon and Ampersand Biomedicines AAV Partnership
Lucid Diligence Brief: Genethon and Ampersand Biomedicines partner to design…
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic…
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration
Lucid Diligence Brief: Apertura Gene Therapy and TSC Alliance Collaboration…
Lucid Diligence Brief: Latus Bio $97 million Series A
Lucid Diligence Brief: Latus Bio $97 million Series A Professional audiences…
Public Health Today—April 24, 2026
This weekly Public Health update highlights key developments across policy,…
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J…
Neuroscience Today—April 15, 2026
This week’s Neuroscience update highlights regulatory progress, biomarker-based…